The fat loss peptide landscape has been completely transformed by GLP-1 agonists — but the story doesn't end there. While semaglutide and tirzepatide dominate headlines, the most effective fat loss protocols combine GLP-1 agonists with growth hormone axis peptides, metabolic activators, and novel compounds like SLU-PP-332. Here's the complete evidence-based ranking.
Triple GLP-1/GIP/Glucagon agonist. 24.2% body weight loss in Phase 2 trials — the highest ever recorded for any pharmacological agent. Not yet FDA-approved but available compounded.
Dual GIP/GLP-1 agonist. 22.5% weight loss in SURMOUNT-1. FDA-approved as Zepbound. Current clinical gold standard.
GHRH analog specifically approved for visceral fat reduction (HIV lipodystrophy). Reduces visceral adipose tissue by 15–20% without the GI side effects of GLP-1 agonists.
Fragment of HGH (176-191) that specifically activates fat metabolism without the growth-promoting effects of full HGH. Mimics HGH's lipolytic action on fat cells.
ERR agonist that activates the same pathways as endurance exercise. Animal studies: 70% further on treadmill, significant fat loss without diet change. Emerging compound.
Beginner protocol: Semaglutide 0.25 mg/week titrating to 2 mg/week + AOD-9604 300 mcg/day. Advanced protocol: Tirzepatide 5–15 mg/week + Tesamorelin 2 mg/day + CJC-1295/Ipamorelin before bed. Cutting edge: Retatrutide 4–8 mg/week + 5-Amino-1MQ 50 mg/day + SLU-PP-332 20 mg/day.
[1] Jastreboff AM et al. (2023). Triple–Hormone-Receptor Agonist Retatrutide for Obesity. NEJM. PMID: 37354011
[2] Jastreboff AM et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. NEJM. PMID: 35658024
[3] Falutz J et al. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV. NEJM. PMID: 17928594
Tell PepBot your specific situation and get a custom protocol tailored to your goals, experience level, and budget.